Incident · Regulatory action
FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance
On July 14 2025 the FDA issued Whoop a warning letter (MARCS-CMS 709755) stating that the Blood Pressure Insights (BPI) daily systolic/diastolic estimation feature on the WHOOP MG / Life membership is an unapproved medical device marketed without clearance, since BP estimation is inherently tied to diagnosis of hypo-/hypertension. Whoop publicly disagreed (Jul 15 2025) and BPI remained accessible; as of mid-2026 the dispute is UNRESOLVED with no recall. The load-bearing marketing-beyond-clearance exemplar of the biometric cohort.
Occurred 2025-07-14 · Whoop (5.0 / MG) at Global · Whoop · Global · Biometric wearables · Investigated by FDA
How to read this record
Incident records on DEPLOY are compiled from public sources (regulatory filings, news reports, and operator disclosures) and reflect what has been reported and tracked to date. They are not legal findings, determinations of fault, or safety ratings, and may be updated as new information is verified. See the sources below for the underlying references.Machine-readable surfaces
- Markdown mirror: /incidents/whoop-bpi-fda-warning-letter-2025.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/incidents/2551f142-584e-48a5-978d-ff8c82023c01
- Data documentation: /data
- Query this programmatically: Deploy MCP
Outcomes (1)
- regulatory actionverified
Revision history (1)
- 2026-06-05 · outcome_class
Outcome rows carry verification_posture independently. Revision events carry basis (verified_court_filing, verified_insurance, reported_press, estimate, undisclosed). The framework records outcomes only when verifiable; absence is honest absence, not a claim of no-impact.
Sources (2)
Common questions
What happened in FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
When did this incident occur?
What robot was involved in FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
Has anyone responded to FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
What is the current status of FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-07-21
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-21
Sources by quality tier
- 1
- primary-fda-database
- FDA database
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance.Deploy Watch
Track this incident.
We notify you when the regulator updates the record, the remedy status changes, or a related incident surfaces.
Canonical ID 2551f142-584e-48a5-978d-ff8c82023c01